HTDS .023(BSNS WIRE) Hard to Treat Diseases Incorporated Announces the Exploration of
ubercin Being Tested in the United States by a Medica
Hard to Treat Diseases Incorporated Announces the Exploration of Tubercin Being
ested in the United States by a Medical Group on Experimental Mice Tests
Business Editors/Health/Medical Writers
OKLAHOMA CITY--(BUSINESS WIRE)--Sept. 11, 2003--Hard to Treat
Diseases Incorporated (Pink Sheets:HTDS) announces today that HTTD has
commenced talks with a medical group in a concerted effort on the
testing of Tubercin(R) in experiments with mice infected with cancer.
The rationale being, these preliminary tests would be helpful for
further FDA considerations as well as reinforcement of results that
Dr. Chung, the inventor of Tubercin(R), has established in the past in
Korea and elsewhere.
The expectation of HTTD is that scientific results recorded by a
third party other than those associated with HTTD will further our
communication efforts in establishing Tubercin(R) as an
immunostimulant for combating cancer.
Due to a nondisclosure agreement, HTTD is not at liberty to
disclose more specifics than the information mentioned above.
As the project develops HTTD will keep you posted.
Operating out of Oklahoma City, Oklahoma, Hard to Treat Diseases
Incorporated ("HTTD") holds the international marketing rights, except
South Korea, to Tubercin, a patented immunostimulant developed for
combating Cancer under medical patent (US Patent 6,274,356). The
unique properties unlike other cancer products are clearly stated in
the abstract summary of the patent... "A carbohydrate complex, which
is a mixture of low molecular-weight polysaccaharides of an
arabinomannan structure extracted from Mycobacterium tuberculosis, is
highly effective in treating various cancer patients without incurring
any adverse side effects."
For more information visit the company's website at
httd.com
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of
1933, as amended. Those statements include statements regarding the
intent, belief or current expectations of the Company and its
management. Such statements reflect management's current views, are
based on certain assumptions and involve risks and uncertainties.
Actual results, events, or performance may differ materially from the
above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not
limited to, our ability to obtain additional financing and access
funds from our existing financing arrangements that will allow us to
continue our current and future operations and whether demand for our
product and testing service in domestic and international markets will
continue to expand. The Company undertakes no obligation to publicly
update these forward-looking statements to reflect events or
circumstances that occur after the date hereof or to reflect any
change in the Company's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events.
--30--BL/mi*
CONTACT: Hard to Treat Diseases Incorporated, Oklahoma City
Gerry Knight, 405/340-3160
ggknight@swbell.net
KEYWORD: OKLAHOMA
INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL PRODUCT
SOURCE: Hard to Treat Diseases Incorporated
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
*** end of story *** |
